Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching
Russia’s biosimilar story is no longer a footnote—it’s a blueprint. And the most important part isn’t the headlines about “cost pressure” or “local manufacturing.” It’s the pipeline: a deliberate, patent-aware buildout that’s positioning Biocad to comp…
